• Transpire Bio appoints Ewan Livesey as Head of Business Development

  Inhaled drug developer Transpire Bio announced that it has hired Ewan Livesey as Head of Business Development. Livesey has more than 30 years experience in business and corporate development and has served in a number… [Read more . . .]

• Nasus announces topline results from Phase 2 clinical study of NS002 epinephrine nasal powder

  Nasus Pharma announced that topline data from its Phase 2 trial of NS002 intranasal dry powder epinephrine versus EpiPen intramuscular epinephrine “demonstrated multiple significant advantages for NS002 across key pharmacokinetic and pharmacodynamic parameters.” The company… [Read more . . .]

• Aptar Pharma will conduct feasibility study of Covirix Medical antiviral in the Orbital DPI

  Australian biopharm Covirix Medical, which is developing a broad-spectrum antiviral, has signed a letter of intent with Aptar Pharma  for a feasibility study evaluating delivery of the antiviral via Aptar’s Orbital dry powder inhaler. The… [Read more . . .]

• Nuance Pharma announces approval of Ohtuvayre ensifentrine inhalation suspension for the treatment of COPD in Hong Kong

  Nuance Pharma announced that the Hong Kong Drug Office has approved Ohtuvayre ensifentrine inhalation suspension for the treatment of COPD. According to Nuance, Ohtuvarye had been available through certain medical facilities in Macau and Hong Kong… [Read more . . .]

• Orbia announces submission of DMF for Zephex 152a LGWP MDI propellant

  Orbia Fluor & Energy Materials (previously Koura, Mexichem) has announced the submission of a drug master file for its HFA 152a MDI propellant, marketed as Zephex 152a. The company kicked off the transition to low global warming potential… [Read more . . .]

• Bespak to increase MDI capacity at its Holmes Chapel site to support Chiesi LGWP transition

• Kenox now offering clinical manufacturing for OINDPs

• Glenmark’s generic equivalent of FloVent HFA fluticasone propionate MDI gets final approval from FDA

• Rein Therapeutics restarts Phase 2 trial of LTI-03 inhaled dry powder synthetic peptide in patients with IPF

• AtaiBeckley announces plans for Phase 3 development of BPL-003 intranasal mebufotenin

More news . . .